Abstract: |
Primary central nervous system lymphoma (PCNSL) is a high or intermediate grade lymphoma that is confined to the brain, cerebrospinal fluid (CSF), eyes, or spinal cord. PCNSL is a highly treatable disease. It is exquisitely chemosensitive and radiosensitive, similar to systemic non-Hodgkin's lymphoma (NHL). Many chemotherapeutic agents have shown some activities as single agents in PCNSL. Methotrexate (MTX) is the most effective and commonly used single agent for the treatment of PCNSL. It has shown excellent responses and control rates with relatively few side effects at intermediate or high doses. MPV, a regimen combining HD-MTX, procarbazine, and vincristine has been reported by several groups, including a large multicenter Radiation Therapy Oncology Group (RTOG) trial as having excellent response and survival when used in combination with whole brain radiotherapy (WBRT). BOMES is a systemic chemotherapy regimen that includes HD-MTX, carmustine, vincristine, etoposide, and methylprednisolone. MTV is a regimen that used an HD-MTX-based combination chemotherapy as a single modality. Cytarabine is the other agent commonly used for the treatment of PCNSL that has excellent penetration into the CSF and the intraocular compartments. © 2006 Elsevier Inc. All rights reserved. |